Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/200923
Title: | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker |
Author: | Martínez Bosch, Neus Vilariño, Noelia Alameda, Francesc Mojal, Sergi Arumí Uria, Montserrat Carrato, Cristina Aldecoa Ansórregui, Iban Ribalta Farrés, Teresa María Vidal, Noemí Bellosillo, Beatriz Menéndez, Silvia Barco, Sonia del Gallego, Oscar Pineda, Estela López Martos, Raquel Hernández, Ainhoa Mesia, Carlos Esteve Codina, Anna Iglesia, Núria de la Balañá, Carme Martínez García, María Navarro, Pilar |
Keywords: | Glioma Tumors cerebrals Gliomas Brain tumors |
Issue Date: | 8-Mar-2023 |
Publisher: | MDPI AG |
Abstract: | Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The beta-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cells12060843 |
It is part of: | Cells, 2023, vol. 12, num. 6 |
URI: | http://hdl.handle.net/2445/200923 |
Related resource: | https://doi.org/10.3390/cells12060843 |
ISSN: | 2073-4409 36980184 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cells-12-00843-v2.pdf | 3.01 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License